First-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1(≥1%) with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. The gene discussed is CD274; the disease is non-small cell lung carcinoma.